Price$75.90+1.33 (+1.78%)
01:30 PM06:45 PM
News · 26 weeks62-8%
2025-12-142026-06-07
Mix3890d
- Insider23(61%)
- SEC Filings7(18%)
- Other4(11%)
- Earnings2(5%)
- Leadership2(5%)
Latest news
25 items- INSIDERSee footnote 3 Jw Asset Management, Llc sold $6,636,886 worth of shares (90,533 units at $73.31) (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- PRAfter Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast InsteadConexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea
- INSIDERDirector Schutter Edward J was granted 2,354 shares, increasing direct ownership by 1% to 177,736 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERDirector Slotkin Bryan was granted 2,354 shares, increasing direct ownership by 8% to 32,610 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERDirector Custin Ann was granted 2,354 shares, increasing direct ownership by 11% to 24,086 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERDirector Lewin Nicholas Sheridan was granted 2,354 shares, increasing direct ownership by 0.22% to 1,079,669 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERDirector Gillin Leslie was granted 2,354 shares, increasing direct ownership by 15% to 18,398 units (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- INSIDERLarge owner Jw Asset Management, Llc sold $1,466,333 worth of shares (20,579 units at $71.25) (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- SECEstablishment Labs Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- PRThe Newest Name on Nasdaq Wants to Help the Body Rebuild ItselfIssued on behalf of Conexeu Sciences Inc.A biotech debut out of Reno is betting that the next wave of medicine won't replace tissue — it'll grow it back.NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News Commentary — Somewhere between a 3D printer, a stem cell lab, and an operating room, a quiet shift has been building in medicine. The premise is no longer to put something foreign into the body when tissue is lost. The premise is to give the body the scaffolding, the cues, and the conditions it needs to grow back what was taken — and then have that scaffolding dissolve, leaving only the patient's own living tissue behind.On May 21, 2026, a new Nasdaq ticker put a public-mark
- PRRoute 92 Medical Announces Appointment of Raj Denhoy as Chief Financial OfficerWEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Raj Denhoy to the role of Chief Financial Officer (CFO) effective today. "Route 92 Medical has built a strong position in neurovascular intervention," said Raj Denhoy, CFO at Route 92 Medical. "The company's innovative technologies, the talented team, and, most importantly, the dedication to the mission of improving patient outcomes, set it apart. I could not be more excited to join the company and look forward to contributing to its continued success."
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Establishment Labs Holdings Inc.SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
- INSIDERDirector Chacon Quiros Juan Jose sold $7,918,872 worth of shares (105,000 units at $75.42) as part of a pre-agreed trading plan (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- SECSEC Form 10-Q filed by Establishment Labs Holdings Inc.10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- INSIDERLarge owner Jw Asset Management, Llc sold $4,537,500 worth of shares (60,000 units at $75.62) (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- SECEstablishment Labs Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- PREstablishment Labs Reports First Quarter 2026 Financial ResultsEstablishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million $19.6 million of Motiva sales in the United States, up 13.3% from Q4 2025 Minimally invasive revenue of $9.1 million for the quarter Gross margin of 70.7% compared to 67.2% in the year-ago period Loss from operations was $6.5 million compared to a loss of $16.
- INSIDERDirector Chacon Quiros Juan Jose sold $5,305,876 worth of shares (75,000 units at $70.75) as part of a pre-agreed trading plan (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- SECEstablishment Labs Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- PREstablishment Labs® Refinances Credit FacilityEstablishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a $300 million senior secured term loan facility with funds managed by Oaktree Capital Management, L.P. ("Oaktree"). The amended and restated facility refinances the company's existing debt and allows access to additional capital to support ongoing operations and future strategic growth initiatives. "This strengthens our capital structure by extending our maturity and enhancing our financial flexibility," said Sandra Harris, Chief Financial Officer of Establishment
- INSIDERDirector Chacon Quiros Juan Jose sold $4,919,478 worth of shares (75,000 units at $65.59) as part of a pre-agreed trading plan (SEC Form 4)4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- SECSEC Form DEFA14A filed by Establishment Labs Holdings Inc.DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
- PREstablishment Labs® to Announce First Quarter 2026 Financial Results on May 6Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2026, before the market opens on Wednesday, May 6, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, Dial: 877-407-8037 (US & Canada) +1 201-689-8037 (international). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com. About Establishment Labs Est
- INSIDERSEC Form 4 filed by Chacon Quiros Juan Jose4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- SECSEC Form DEFA14A filed by Establishment Labs Holdings Inc.DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
ESTA FAQ
7 questionsWhat does Establishment Labs Holdings Inc. do?
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through...Where does ESTA stock trade?
Establishment Labs Holdings Inc. (ESTA) is listed on NASDAQ.What sector and industry is ESTA in?
Establishment Labs Holdings Inc. operates in the Health Care sector, Industrial Specialties industry.When did Establishment Labs Holdings Inc. go public?
Establishment Labs Holdings Inc. (ESTA) completed its IPO in 2018.What are analysts saying about ESTA?
Establishment Labs Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2025-08-20. Recent price targets cluster around $4800.00.What companies are similar to ESTA?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare ESTA side-by-side with any of them on Quantisnow.How can I track ESTA on Quantisnow?
Quantisnow aggregates Establishment Labs Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ESTA to receive live email and push alerts on every new disclosure.